Oral administration represents 48.00% of the administration route category in 2026. The hormone replacement therapy market was valued at USD 20.1 billion in 2025, is projected to reach USD 37.8 billion by 2036 and is forecast to post a 5.9% CAGR between 2026 and 2036, creating an incremental opportunity of USD 16.5 billion.